文献速递淋巴瘤

慢性淋巴细胞白血病中的SETα与SETβ mRNA异构体

SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2018-11-15

研究探讨慢性淋巴细胞白血病(CLL)中SET基因可变剪接异构体SETα和SETβ mRNA水平与疾病严重程度的关系,发现其与总生存期和首次治疗时间显著相关,且SETα/SETβ比值升高可在IGHV突变和FISH有利分组中鉴别出更具侵袭性的病程,并在独立机构CLL队列中验证。

要点

  • SETα和SETβ mRNA水平与CLL患者总生存期及首次治疗时间显著相关。
  • SETα相对SETβ mRNA升高可在IGHV突变和FISH有利分组中识别更具侵袭性病程的患者。
  • SET mRNA与疾病结局的关系在独立机构CLL队列中得到验证。

核心结论

  • SET基因可变剪接(SETα和SETβ)影响CLL生物学和患者结局,SETα/SETβ比值升高可在传统有利风险分类中鉴别更具侵袭性的病程。

研究设计与样本

  • 研究检测CLL患者样本中SETα和SETβ mRNA水平,并与疾病严重程度(总生存期和首次治疗时间)进行关联分析,另用来自独立机构的CLL队列样本验证SET mRNA与疾病结局的关系。

主要发现

  • SETα和SETβ mRNA水平与CLL患者疾病严重程度(总生存期和首次治疗时间)显著相关。
  • SETA相对SETB mRNA升高可在IGHV突变和FISH有利分层组中区分出更具侵袭性病程的患者。
  • 在独立机构CLL队列中验证了SET mRNA与疾病结局的可比关系。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alteration in RNA splicing is implicated in carcinogenesis and progression. Mutations in spliceosome genes and alternative splicing of other genes have been noted in chronic lymphocytic leukaemia (CLL), a common B cell malignancy with heterogeneous outcomes. We previously demonstrated that differences in the amount of SET oncoprotein (a physiological inhibitor of the serine/threonine phosphatase, PP2A) is associated with clinical aggressiveness in patients with CLL. It is unknown if alternative splicing of gene transcripts regulating kinases and phosphatases affects disease pathobiology and CLL progression. We show here for the first time that mRNA levels of the alternatively spliced SET isoforms, SETA and SETB (SETα and SETβ), significantly correlate with disease severity (overall survival and time-to-first-treatment) in CLL patients. In addition, we demonstrate that relative increase of SETA to SETB mRNA can discriminate patients with a more aggressive disease course within the otherwise favourable CLL risk classifications of IGHV mutated and favourable hierarchical fluorescence in situ hybridisation groups. We validate our finding by showing comparable relationships of SET mRNA with disease outcomes using samples from an independent CLL cohort from a separate institution. These findings indicate that alternative splicing of SET, and potentially other signalling cascade molecules, influences CLL biology and patient outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Brander DM, Friedman DR, Volkheimer AD, et al. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. Br J Haematol. 2018. PMID: 30443898. doi:10.1111/bjh.15677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。